AB0894 Efficacy and Safety of Guselkumab in Biologic-Naïve Patients With Active Axial Psoriatic Arthritis: Study Design of a Phase 4, Randomized, Double-Blind, Placebo-Controlled Trial

Gladman, D.D., Mease, P.J., Bird, P. et al. (13 more authors) (2022) AB0894 Efficacy and Safety of Guselkumab in Biologic-Naïve Patients With Active Axial Psoriatic Arthritis: Study Design of a Phase 4, Randomized, Double-Blind, Placebo-Controlled Trial. In: Annals of the Rheumatic Diseases. EULAR 2022 European Congress of Rheumatology, 01-04 Jun 2022, Copenhagen, Denmark. BMJ , pp. 1574-1575.

Metadata

Authors/Creators:
  • Gladman, D.D.
  • Mease, P.J.
  • Bird, P.
  • Soriano, E.
  • Chakravarty, S.D.
  • Shawi, M.
  • Xu, S.
  • Quinn, S.
  • Gong, C.
  • Leibowitz, E.
  • Tam, L.S.
  • Helliwell, P.
  • Kavanaugh, A.
  • Deodhar, A.
  • Østergaard, M.
  • Baraliakos, X.
Dates:
  • Published (online): 23 May 2022
  • Published: 23 May 2022
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Inflammatory Arthritis (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 22 Aug 2023 13:23
Last Modified: 22 Aug 2023 13:23
Status: Published
Publisher: BMJ
Identification Number: https://doi.org/10.1136/annrheumdis-2022-eular.1551
Related URLs:

Export

Statistics


CORE (COnnecting REpositories)